Angiogenesis, views and news. The 93rd annual meeting of the American Association for Cancer Research. April 6-10 2002, Moscone Convention Center, San Francisco, USA.
The 93rd Annual Meeting of the American Association of Cancer Research was held in San Francisco, CA, USA. It was one of the largest conferences of its kind covering all aspects of cancer research with 6000 scientific presentations over a period of 5 days. The following meeting highlights are focused on a few selected developments in the field of tumour-induced angiogenesis, attempting a synthesis between educational sessions and original scientific presentations. Two important shifts in paradigms were reported at that meeting involving the biology of tumour-induced angiogenesis. Firstly, the generation of new blood vessels was demonstrated to dramatically depend on bone marrow-derived circulating endothelial precursor cells, thereby supplementing existing concepts of vessel generation by migration and proliferation of pre-existing mature endothelial cells. Secondly, the genetic stability of endothelial cells circumventing resistance to antiangiogenic therapy was challenged by the observation of resistance to hypoxia, which developed in tumour cells following antiangiogenic therapy. Both aspects are discussed in the following chapters with respect to their possible impact on the development of therapeutic strategies involving angiogenesis inhibition.
Lode
Holger N
HN
Charit Children's Hospital, Forschungshaus 2.0407, Augustenburger Platz 1, 13353 Berlin, Germany. holger.lode@charite.de
Wenkel
J
J
Gaedicke
Gerhard
G
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D001854:Bone Marrow Cells / Q000166:cytology; D042783:Endothelial Cells / Q000378:metabolism; D006801:Humans; D000860:Hypoxia; D009369:Neoplasms / Q000473:pathology*; D009389:Neovascularization, Pathologic; D013234:Stem Cells / Q000166:cytology
D020533:Angiogenesis Inhibitors